Showing 1 - 10 of 307,909
EU countries closely regulate pharmaceutical prices whereas the U.S. does not. This paper shows how price constraints affect the profitability, stock returns, and R&D spending of EU and U.S. firms. Compared to EU firms, U.S. firms are more profitable, earn higher stock returns, and spend more on...
Persistent link: https://www.econbiz.de/10012465985
Persistent link: https://www.econbiz.de/10002103016
Persistent link: https://www.econbiz.de/10011708133
public expenditure, limiting financial exposure of patients, improving access to pharmaceuticals, and stimulating competition …
Persistent link: https://www.econbiz.de/10010224844
manufacturer) on pharmaceutical regulation in a North-South framework with a firm's endogenous decision to export to the South … via reimbursement limits. Parallel trade may relax regulation in the source country of parallel imports (South) and … intensify regulation in the destination country (North): In the source country, parallel trade may relax regulation both under a …
Persistent link: https://www.econbiz.de/10011986314
public expenditure, limiting financial exposure of patients, improving access to pharmaceuticals, and stimulating competition …
Persistent link: https://www.econbiz.de/10014150467
Pharmaceuticals in the Environment: Regulatory and Nonregulatory Approaches -- Current Findings -- Regulatory Options …
Persistent link: https://www.econbiz.de/10012685632
Persistent link: https://www.econbiz.de/10003937245
Persistent link: https://www.econbiz.de/10001681733
to health care, including pharmaceuticals. Given pressure on public budgets and rising expenditure for healthcare …, national governments have introduced mechanisms to regulate healthcare services provision and set prices of pharmaceuticals. As … pharmaceuticals and, in particular, its price-setting system. The bill endorsed by the German parliament in late 2010 will …
Persistent link: https://www.econbiz.de/10013018181